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Abstract
From the molecular mechanism of antagonist unbinding in the β1 and β2 adrenoceptors
investigated by steered molecular dynamics, we attempt to provide further possibilities of ligand
subtype and subspecies selectivity. We have simulated unbinding of β1-selective Esmolol and β2-
selective ICI-118551 from both receptors to the extracellular environment and found distinct
molecular features of unbinding. By calculating work profiles, we show different preference in
antagonist unbinding pathways between the receptors, in particular, perpendicular to the
membrane pathway is favourable in the β1 adrenoceptor, whereas the lateral pathway involving
helices 5, 6 and 7 is preferable in the β2 adrenoceptor. The estimated free energy change of
unbinding based on the preferable pathway correlates with the experimental ligand selectivity. We
then show that the non-conserved K347 (6.58) appears to facilitate in guiding Esmolol to the
extracellular surface via hydrogen bonds in the β1 adrenoceptor. In contrast, hydrophobic and
aromatic interactions dominate in driving ICI-118551 through the easiest pathway in the β2
adrenoceptor. We show how our study can stimulate design of selective antagonists and discuss
other possible molecular reasons of ligand selectivity, involving sequential binding of agonists and
glycosylation of the receptor extracellular surface.
Keywords
adrenergic receptors; drug design; G protein-coupled receptors; molecular dynamics; selectivity
A major challenge in drug design is to find a small molecule that selectively binds to its
target receptor and does not cause unintended side-effects by binding to other similar
receptors. When a high-resolution structure of a receptor is available, a structure-based drug
design paradigm is applicable to identify not only a small molecule ligand with high binding
affinity, but also with good selectivity. However, the binding site architecture of closely
related receptor subtypes and subspecies are often highly homologous, making the search for
highly selective drugs, which relies on docking of small molecules into the crystal structures
of receptors, impractical. This is particularly evident in the design of selective orthosteric
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agonists and antagonists in such a large and pharmaceutically important class of drug targets
as the G protein-coupled receptors.
One strategy for improving selectivity is to account for differences in the ligand binding and
unbinding pathways of closely related receptors caused by non-conserved residues outside
the drug-binding site. In this work, we aim to explore the dynamic and kinetic causes of
antagonist subtype selectivity in the β1 and β2 adrenergic receptors (AR). β1AR and β2AR
represent one of the most extensively characterized subfamilies of the G protein-coupled
receptors, which are expressed in many cell types and play a pivotal role in regulation of the
cardiovascular, pulmonary, endocrine and central nervous systems (1). Antagonists of the
adrenergic receptors (β-blockers) are hallmark drugs for treatment of ischaemic heart
disease, hypertension and congestive heart failure (1,2). Although the primary
cardiovascular use of β-blockers is antagonism of β1AR responses in the heart, their use
may also result in antagonism of β2AR in airways, resulting in bronchospasm (1,2). To
avoid this side-effect, β1AR-selective antagonists are required.
To identify the dynamic and kinetic bases of antagonist selectivity, we have studied the
unbinding process of two selective antagonists, Esmolol, which is 76-fold selective to β1AR
(3–5), and ICI-118551, which is 550-fold β2AR selective (6,7) (Figure 1), from human
β1AR and β2AR, using a molecular dynamics approach. Given that a computer-aided drug
design campaign requires fast evaluation of potential binders, and monitoring of ligand
binding and unbinding requires a microsecond time scale that is not affordable in a high-
throughput level, we accelerated unbinding by applying an external force to pull the
antagonist from the binding site in several directions using steered molecular dynamics
(sMD). Through the use of multiple sMD simulations of ligand unbinding events, the
statistical importance of unbinding pathways, as well as specific residue interactions
important to them, can be analysed and key receptor conformations possessing characteristic
interactions can be exploited in future drug design efforts.
Recent simulations of the unbinding pathways of the non-selective inverse agonist Carazolol
from β2AR using the random acceleration molecular dynamics method have shown that
unbinding occurs primarily through the extracellular region of β2AR and only rarely through
transmembrane helices, suggesting that pathways through the extracellular surface provide a
specific route to ligand entry (8). To further investigate this phenomenon, we have
performed simulations in which the selective antagonists are pulled from the binding site to
the extracellular surface along three directions: one perpendicular to the membrane and two
lateral paths. We use the estimated free energy change of ligand unbinding based on the
preferable pathway to correlate the experimentally observed ligand selectivity. From
monitoring the impact of different interactions on the process of ligand unbinding, we
delineate common and uncommon features of the unbinding process between two receptors
and two ligands, along with their implications for structure-based drugs design studies. We
also compare our results with the recent publication of non-selective ligand binding to β2AR
using conventional MD (9) and non-selective ligand unbinding from β1AR and β2AR using
steered MD (10). Finally, we discuss other potential reasons for different ligand binding and
unbinding pathways between the receptors, which can account for structural constraints in
the design of selective small molecule modulators.
Methods
Preparation of ligand-protein complexes for simulations in the hydrated phospholipid
bilayer
To be consistent with ligand selectivity analysis in the human adrenergic receptors, we
chose the available high-resolution crystal structure of the human β2AR (2.4 Å) (PDB ID:
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2RH1) and the 3D model of human β1AR was constructed based on this structure using the
PRIME MODULE 2.2a of the SCHRODINGER SUITE 9.0b. The 3D models of receptors were prepared for
ligand docking studies using the Schrodinger protein preparation utility. The docking of
ICI-118551 and Esmolol into the structures of β1AR and β2AR was performed with Glide
5.6c with the Extra Precision algorithm. Ligands were processed using LIGPREP 2.4 with the
OPLS 2005 force filedb (11,12). The investigated antagonists were close structural
analogues of the ligands in the crystal structures, thus the docking poses similar to the
crystal structures were quickly identified in the docking studies. Concurrent to this study, the
crystal structure of β2AR in complex with ICI-118551 was published, which exhibit a nearly
identical binding pose of ICI-118551 to our docking pose (13). The superposition of the
crystallographic and computational coordinates of the binding site with ICI-118551 is shown
in Figure S1 of the Supporting Information. The System Builder of Maestro GUI 9.0 was used
to embed four ligand-receptor complexes and the unoccupied receptors into a bilayer
composed of 1-palmitoyl-2-oleoylphosphatidylcholine, solvate the extracellular and
intracellular sides of the bilayer, neutralize the biomolecular system and preserve
physiological pH using 0.15 M sodium chloride concentration. The final biomolecular
systems contained around 75 000 atoms.
Biomolecular dynamics
Conventional and sMD were performed using the DESMOND package 2.2 (14). The temperature
and pressure were controlled at 300 K and 1 atm, respectively, using the Berendsen
algorithm. Long-range electrostatics was calculated by means of the Particle Mesh Ewald
Method (15). The OPLS2005 force field was used for all simulationsb (11,12). The
biomolecular systems were equilibrated using the following steps: (i) energy minimization
(2000 cycles) of the solvent and lipid bilayer, while the ligand-receptor complex was frozen,
using the conjugate gradient algorithm up to a convergence threshold of 0.5 kcal/mol/Å; (ii)
heating of the system to 10 K in the NVT ensemble over 12 pseconds; (iii) heating of the
system from 10 to 300 K in the NPT ensemble over 12 pseconds; (iv) equilibration for 7–9
nseconds at 300 K in which the complexes were still frozen; (v) equilibration for 2 nseconds
in which the protein backbone was restrained; (vi) equilibration for 2 nseconds with no
restraints. Following equilibration, the 30 nseconds production runs were carried out in the
NPT ensemble. The steered MD simulations were tested with a pulling speed of 0.005, 0.01,
0.015, 0.02 and 0.03 Å/psecond and a spring constant of 4.5, 4, 3.5, 2.5 and 1.5 kca/mol/Å2
(16,17). The pulling speed of 0.02 Å/psecond and spring constant of 4.0 kcal/mol/Å2 were
selected for the detailed studies presented below. Ten pulling simulations in each chosen
direction were performed with different initial velocities. Figure 2 was prepared in PYMOL
0.99d and movies were made in Maestrob.
Analysis of MD trajectories
Hydrogen bond occupancy along simulations trajectories was computed in VMD 1.8.9 (18).
Hydrogen bonds with a defined threshold for distance of 3 Å and angle of 35° were
calculated in VMD 1.8.9 (18). Carbon atoms at distance 1.4–5 Å were selected for
hydrophobic contacts in Maestro of the SCHRODINGER SUITE 9.0b. Water-mediated contacts at a
distance of 3 Å with a minimum donor angle of 120° and a minimum acceptor angle of 90°
were computed in Maestro. The radius of gyration of the lateral channel involving helices 5,
6 and 7 was calculated by selecting Cα atoms of F193, T195, H296 and N293 with VMD
aPRIME 2.0. (2008) New York, NY, USA: Schrödinger, LLC.
b(2010) New York, NY, USA: Schrodinger, LLC.
cGLIDE 5.6. (2009) New York, NY, USA: Schrödinger, LLC.
dThe PyMOL Molecular Graphics System 0.99. (2002) San Carlos, CA, USA: DeLano Scientific, LLC.
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(18). The work required pulling antagonists from the adrenergic receptors and ΔPMF were
calculated using the VMD scripts.
Grid generation
The hydrogen bond acceptor and hydrophobic probes for the selected snapshots from sMD
trajectories were calculated in SITE-MAP V2.5 of Schrodingere. The probes were placed in the
receptors at a radius of 6 Å from the ligand in the selected snapshot of the MD trajectory.
Results and Discussion
Dynamics of the extracellular side of the β1 and β2 adrenergic receptors with the selective
ligands
We started our study with the performance of conventional molecular dynamics (cMD)
simulations of the human β1 and β2 adrenergic receptors (AR) with docked Esmolol and
ICI-118551 to initiate comparison of dynamics of the receptor extracellular cavity and
ligand binding modes in each receptor, to define the ligand pulling directions from the
receptor and to produce the starting coordinates for ligand unbinding simulations. The
protein conformations stabilized following 2 nseconds of equilibration, at which point the
root-mean-square deviations of protein backbone and ligand heavy atoms converged around
2 and 0.9 Å for the Esmolol-β1AR complex, 2.5 and 0.6 Å for the ICI-118551-β1AR
complex, 2.1 and 0.6 Å for the Esmolol-β2AR complex and 1.9 and 0.7 Å for the
ICI-118551-β2AR. The 30 nseconds cMD simulations of the complexes revealed higher
fluctuation of the extracellular cavity, involving the extracellular regions of the helices and
loops, in β1AR than in β2AR. As expected, the complex of the receptors with the selective
antagonist was more rigid than the complex with the non-selective antagonist. The root-
mean-square fluctuations of the Cα atoms of the extracellular cavity for two receptors are
shown in Figure S2 in the Supporting Information. In Figure 2, we show one equilibrated
snapshot of the extracellular cavity for each receptor, displaying amino acid residues of the
extracellular side, together with the schematic representation of the antagonist binding site
depicting the key residues involved in the interactions with the ligands.
In β1AR, a salt bridge between E205EL2 and R351EL3 was observed, with occupancy of
more than 20% in each simulation, that dynamically connects the second extracellular loop
(EL2) and the third extracellular loop (EL3) from the lateral side of the extracellular cavity
in β1AR (Figure 2A). This salt bridge has also been observed in recent simulations of human
β1AR by Gonzalez and co-workers (10) using the CHARMM force field. It is likely unique
to the human β1AR as the residue corresponding to E205EL2 in turkey β1AR (Q188) is
located 3.5–10 Å from the arginine side chain in the available crystal structures (19–21). In
β2AR, these residues are substituted to E180EL2 and D300EL3.
Residues D192EL2 and K3057.46 (The Ballesteros and Weinstein nomenclature in
superscript (22)), in β2AR form a salt bridge that splits the β2AR extracellular cavity into
two sub-cavities (Figure 2B). This salt bridge, which is present in five of seven crystal
structures of inactive β2AR bound to ligands (13,23,24), has an occupancy near 80% in
simulations of the receptor complexes with Esmolol and ICI-118551. This is twice more
than in our simulations of the ligand-free receptor, suggesting that antagonists stabilize this
interaction, which likely holds the receptor in the inactive state. Although site-directed
mutagenesis of D192EL2 and K3057.46 with emonstration of the role of these residues in
ligand binding has not been documented in the literature, the different influence of ligands
on the stability of the D192EL2-K3057.46 salt bridge has been recently described by an NMR
eSITEMAP 2.4. (2010) New York, NY, USA: Schrödinger, LLC.
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study via monitoring different resonances of radiolabeled K3057.46 in the presence of
agonists and antagonists (25). This mechanism of receptor modulation by extracellular salt
bridges through their breakage and appearance was observed in the free fatty acid receptor 1
using mutagenesis and molecular modelling (26). β1AR misses this salt bridge as K3057.46
is substituted to D3567.46.
Hydrogen bonds between the secondary amine and β-hydroxyl group of both ligands with
D138/1133.32, N363/3127.39 and Y367/3167.43 (Figure 2C,D) were preserved during
simulations with β1AR and β2AR, while the aromatic ring of ICI-118551 was buried deeper
in the pocket than Esmolol in both receptors. The ester group of Esmolol was engaged in
hydrogen bonding with N344/2936.55 and S229/2045.43 in 40% and 8% of the simulations
time in β1AR, while in β2AR this was reduced to 13% and 3% of the simulation time. The
varying interactions of N344/2936.55 are owing to different accessibilities of N344/2936.55
in the receptors; N344/2936.55 is exposed to the extracellular cavity with χ1 mainly in the g−
rotameric state, (171 ± 8°) in β1AR, whereas it is buried into the receptor with χ1 in the t
rotameric state, (−87 ± 25°) in β2AR. These different states are owing to a hydrogen bond
between N2936.55 and Y3087.35 in β2AR, shown in the available crystal structures
(13,21,22,25,26), that is disrupted by the substitution of Y3087.35 to phenylalanine in β1AR
(Figure 2C,D) (13,23,24,27,28). Our simulations show that this hydrogen bond is formed
more than 50% of the time in the complexes of β2AR with Esmolol and ICI-118551,
reinforcing the non-direct role of the N2936.55-Y3087.35 interaction in ligand selectivity. The
impact of Y308A7.35 and N2936.55Q/L/A mutations in the reduction of β2AR ligand
selectivity and, interestingly, the increase ligand selectivity for N2936.55F has been shown
by mutagenesis studies (29–31). This hydrogen bond was constantly monitored in the MD
simulations of β2AR in the complex with carazolol by Vanni and co-workers (32). In the
unoccupied receptor, the N2936.55-Y3087.35 hydrogen bond is present in only 20% of the
simulations time, suggesting that ligand binding facilitates this interaction.
The final snapshots of the 30 nseconds cMD simulations were used as starting points for
sMD calculations. To investigate the impact of structural and dynamics differences of the
extracellular cavity in ligand recognition, we pulled antagonists along three distinct
directions, one perpendicular to the membrane (path B) and two lateral – one to the side of
helices 1, 2 and 7 (path A) and the other to the side of helices 5, 6 and 7 (path C) (Figure 2).
Pulling of selective antagonists from the β1 and β2 adrenergic receptors
We used a steered MD algorithm to pull the antagonists from the binding pocket over 2
nseconds of simulation time. Pulling was induced along a particular pathway by the
introduction of an external biasing potential along a predefined vector (as shown in Figure
2). The choice of the receptor and the antagonist pulling atoms (Figure 1) determined three
ligand unbinding pathways, where the pulling directions were defined by the centre of mass
of the receptor atoms are shown in Table 1. We tested simulations at varying pulling
velocities and spring constants, which all exhibited unbinding in a similar fashion, and chose
sMD parameters to balance computational cost with simulation accuracy (see Methods
section). To investigate the pulling mechanics of selective antagonists, Esmolol and
ICI-118551 from β1AR and β2AR in chosen directions, we calculated the rupture force
profile along the pathways. Figure 3 shows the average force profile for the perpendicular
and two lateral pathways of the receptors releasing either Esmolol or ICI-118551 projected
onto the unbinding simulation time and the ligand separation distance from the original
position. For each pathway, the average values were taken from ten trajectories simulated
with a pulling velocity of 0.02 Å/psecond and a spring constant of 4.0 kcal/mol/Å2.
Generally, complete unbinding of the ligand occurred within 1–1.5 nseconds. Although the
receptors have a similar pattern of the force profile graphs between the pathways, there are
notable differences in the size and dynamics of the force peaks, suggesting distinct
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properties of the unbinding process. In β1AR, the average force peak in path B had lower
values than in paths A and C for both Esmolol and ICI-118551, while in β2AR the force
peaks along path C are lower than in paths A and B. To estimate the work performed by the
antagonist during unbinding along chosen pathways we integrated the force curve over the
ligand separation distance from the ligand original position (Figure 3). The computed work
highlights the different preference in unbinding pathways and pulling of selective and non-
selective antagonists between the receptors. In particular, less work is required to pull
antagonists from path B in β1AR and, among antagonists, more work is required to pull the
β1AR-selective antagonist in chosen pathways; less work is needed to pull the antagonists
from path C and similarly, the β2AR-selective antagonist is required more work to apply in
β2AR. Jarzynski's equality states that the average work applied on the replicated ensembles
can represent, in the first approximation, the overall change in the free energy between
bound (a) and unbound (b) state or the potential of mean force (ΔPMF) along a reaction
coordinate:
where β is 1/(kbT), kb is Boltzmann constant and T is the temperature in Kelvin. Because in
path B of β1AR and path C of β2AR, the ligands are needed the smallest work to perform,
we use these pathways to compare ΔPMF with the experimental ligand selectivity. Although
the calculation of the free energy change accurately requires numerous replicates (100–
1000), we nevertheless hope that our multiple but still few simulations will provide a
relative estimate of the free energy of ligand unbinding and binding. We repeated unbinding
simulations for the preferable pathways (path B in β1AR and path C in β2AR) another ten
times and calculated ΔPMF using the Jarzynski's equality formula. The ΔPMF of Esmolol
and ICI-118551 were −7 and −6 kcal/mol in path B of β1AR and −6.3 and −7.9 kcal/mol in
path C of β2AR, respectively. The ΔPMF of ligands confirms antagonist preferences
between the receptors. The calculated ΔPMF values from the available experimental
constants of inhibition (Ki) (Figure 1) for Esmolol, were −7.3 and −6.8 kcal/mol and, for
ICI-118551 were −10 and −12.6 kcal/mol, in β1AR and β2AR, respectively. The ΔPMF of
unbinding from β2AR is slightly lower from experimental calculated values, suggesting the
importance of additional replicates to increase accuracy. Below, we compare unbinding of
each selective antagonist from both receptors with characterization of the specific
interactions that contribute to ΔPMF.
Pulling from the β1 adrenergic receptor
Because path B required the smallest work to apply, we hypothesized that specific molecular
features along this path might result in the experimentally observed ligand specificity of
selective and non-selective antagonists. To examine this, we compared the unbinding of
antagonists along path B and decomposed the rupture force into specific interactions,
involving hydrogen bonds, hydrophobic, and water-mediated contacts, the results of which
are shown in Figure 4 for one characteristic trajectory. From pharmacological studies,
Esmolol binds in β1AR more tightly than ICI-118551, thus more work is required to pull it
out from the receptor, as indicated in the work profiles. After some jiggling resulting from
the bias potential, involving the iterative breakage and appearance of the hydrogen bond
between the ester group and N3446.55, Esmolol ultimately lost its first hydrogen bond with
the receptor via water-bridged interactions at early as 350 pseconds, corresponding to the
first peak in the force profile. This facilitated the movement of the aromatic ring of Esmolol
towards the extra-cellular surface. Around 650 pseconds, the secondary amine and β-
hydroxyl group of the ligand broke hydrogen bonds with N3637.39 and Y3677.43, and the
ligand approached the extracellular surface while still retaining the salt bridge with D1383.32
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in the binding site. The centre peak in the force profiles corresponds to the breakage of the
salt bridge at the binding site, which happens after a minimum of 800 pseconds. After
breakage of the interaction with D1383.32, the amine of the ligand established interactions
with D217EL2 in multiple trajectories and occasionally with D356EL3, followed by diffusion
into the water within 250 pseconds. In the ligand binding process, these two negatively
charged residues likely serve as beacons that recognize the charged amino group of a ligand
within the solvent environment. In the case of ICI-118551, the applied force caused the
aromatic moiety to move towards the receptor surface, which was followed by the breakage
of interactions with the original binding site residues. The unbinding process occurred
quicker for ICI-118551 then for Esmolol.
The disruption of ligand-receptor interactions followed a similar pattern in other pulling
directions. The ester group, released from its original interactions with binding site residues
in β1AR, formed hydrogen bonds with T220EL2 at 400–550 pseconds, followed by forming
interactions with K3476.58 at 600–700 pseconds that lasted for 200 pseconds in seven of the
simulation trajectories. After breakage of water-bridged interactions with K3476.58, the ester
group formed its last interaction with the backbone of F218EL2. This profile of continuous
interchange of hydrogen bond interactions between the ester and the receptor along the
unbinding pathway is shown in Figure 5 and Movie S1 (where the role of K3476.58 is
highlighted). We also observed direct and water-bridged interactions between the ester
group and K3476.58 in five trajectories along path A. In contrast, ICI-118551 did not form
any hydrogen bonds with K3476.58. In both cMD and sMD simulations, K3476.58 moved
freely in the cavity for a majority of the time and formed a salt bridge with E352EL3 in only
8% of the simulation time. Therefore, we propose that K3476.58 might act as a `hydrogen
bond translator' that interacts with a specific group of the ligand and facilitates the
movement of the selective antagonist between the receptor extracellular surface and the
binding site, along with preventing the exit of the molecule from the binding cavity.
Potentially, during the ligand binding process, this residue might also facilitate Esmolol to
enter the binding cavity with an orientation that would result in having optimal interactions
with the binding site residues.
Antagonists formed interactions with aromatic and aliphatic residues for 53% and 47% of
the simulation time, correspondently. Helix 2 has been proposed to play a role in β1-
selectivity of (−)-RO363 (33), and it is observed that the non-conserved I1182.64 held
interactions with the ligand in 10% of the unbinding time, suggesting the potential role of
I1182.64 in ligand selectivity, which was not found for (−)-RO363. During unbinding, the
side chains of F218EL2 and F3597.35, which form the gate to the extracellular cavity, moved
away from each other, increasing the centre of mass distance between the aromatic rings
from 8 to 12 Å(Figure 6A,B). Once the ligand exited the receptor, their separation distance
decreased to a minimum of 5 Å, similar to the value observed in the unoccupied receptor
(Figure 6C). This suggests that these two phenylalanines form gates that open and close
during ligand binding, discriminate whether the ligand can enter into the binding cavity, and
if so, guide the ligand into the receptor.
As the antagonists was pulled from the binding cavity, water-mediated interactions formed
to replace protein-ligand interactions (Figure 4). For example, the breakage of the salt bridge
between the amine group and D1383.32 occurred when a water molecule reached the salt
bridge, and was often observed to initially form interactions with D1383.32, followed by
interacting with the secondary amine, resulting in the breakage of the direct protein-ligand
interaction. To appreciate the impact of water molecules on unbinding, we simulated the
ligand escape in vacuum and found the maximum value of the rupture force increased to 32
kcal/mol/Å (twice that observed in the solvated systems), suggesting that water-mediated
interactions facilitate the ligand's movement along the extracellular cavity (Figure S3).
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Movement of antagonists along path B led to the flooding of 15 water molecules into the
binding cavity (Figure S4) through the region surrounding the secondary amine of the
antagonists.
Path C in β1AR required the highest force for both ligands. When pulled along this
trajectory, both ligands exited through the EL2 in 6–7 simulations with the rupture forces
reaching up to 20 kcal/mol/Å. In the case of b2AR, the ligand escaped along path C without
going through EL2 in all trajectories. EL2 has high mobility and therefore tends to cover the
extracellular mouth in β1AR, whereas it has a rigid position and localizes close to the side of
helices in b2AR owing to restriction caused by the extracellular salt bridge. The average
root-mean-square deviation values of the β1AR backbone along three pathways, provided in
Figure S5, show higher fluctuation of the receptor in path C, indicating that large structural
rearrangements are required to allow the ligand to exit the receptor along this pathway. This
is due not only to a steric clash with the hydrophobic tail of K3476.58, but was also a result
of the required breakage of the salt bridge between E205EL2 and R351EL3 in several
trajectories, which formed and remained stable during equilibration in our cMD simulations.
Pulling from the β2 adrenergic receptor
Simulations of ligand unbinding from b2AR showed that, contrary to what was observed for
β1AR, path C required the application of the smallest force to bring the antagonists to the
surface. This is consistent with recently published work on binding of the β-adrenoblockers
to b2AR using cMD, where the authors showed that ligands bind preferably to the receptor
from the extracellular side of helices 5, 6 and 7 (9). In our simulations, we monitored the
hydrogen bond network between the side chains of N2936.55, H2966.58 and Y3087.35 (Figure
7A,B), which drives them close to helix 6, enlarges the lateral channel, and thus facilitates
the ligand's movement along path C. To monitor the changes in the size of the lateral
channel, we calculated the radius of gyration along path C, as shown in Figure 7C. The
hydrogen bond network that exists only during the unbinding process increases the radius of
gyration compared to its value in the cMD of the antagonist-receptor complexes (Figure
7D). The dynamics of this network of interactions in the unbinding of ICI-118551 from
b2AR through path C are shown in Movie S2.
In paths A and B, the higher peaks in the force profile appear to be a result of the antagonists
breaking the D192EL2-K3057.46 salt bridge at the extracellular part, in addition to the
disruption of the salt bridge in the binding site. Along these paths, the antagonists escaped
without the breakage of the salt bridge in only seven of 40 trajectories, while the unbinding
along pathway C did not require the breakage of the salt bridge in all MD trajectories. The
average root-mean-square deviation values of the b2AR backbone along the three pathways,
provided in the Figure S5, shows larger deviation of the receptor in paths A and B at the
time of the salt bridge breakage, supporting a somewhat obstacle role of the salt bridge.
The sequence of breakage of the original interactions during the unbinding of Esmolol and
ICI-118551 was similar to that in β1AR. Figure 8 shows the time dependence of different
ligand-protein interactions along unbinding pathway C. The ester group of Esmolol formed
and broke interactions with S2045.43 and occasionally with N2936.55 at the beginning of the
unbinding process, while final breakage of this interaction resulted in the first peak in the
force profile. Overall, the ester group of Esmolol formed fewer hydrogen bonds along the
unbinding pathway in b2AR than in β1AR, as shown in Figure 5, while both ligands left the
receptor surface by breaking interactions with D300EL3. Our data, as well as the recently
published cMD simulations of ligand binding to b2AR, suggest that D300EL3 likely plays
the recognition role of the charged amine of the ligand in a cellular environment, similar to
D217EL2 and D356EL3 in β1AR.
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It was also observed that Esmolol escaped quicker than ICI-118551 from b2AR. This is a
result of ICI-118551 forming extra aromatic and hydrophobic interactions with Y3087.35,
H2966.58, F193EL2 and F194EL2 through its large hydrophobic moiety along the pathway, as
shown in Figure 8. F194EL2 formed hydrophobic interactions with ICI-118551 and followed
the ligand to the solvent environment in several trajectories through movement of its
backbone and side chain. The distance between the centre of the aromatic ring of H2966.58
and antagonists remained 5Å during 250ps in several trajectories, suggesting formation of
aromatic interactions. We propose that the side chain of F194EL2 and H2966.58 steer the
ligand into the binding site during a binding event. Unlike their counterparts F218EL2 and
F3597.35 in β1AR, the distance between the centre of the aromatic ring of F193EL2 and
Y3087.35 showed only small fluctu ations around 8–9 Å throughout the simulations,
indicating that the narrow cleft is enough to progress the antagonist into the binding pocket
in β2AR (Figure S6). This distance is preserved when the antagonists were pulled to the
direction of path B. Because the mobility of F193EL2 is restricted by the D192EL2-K3057.46
salt bridge and Y3087.35 is constrained by the hydrogen bond with N2936.55, F193EL2 and
Y3087.35 thus function as open gates.
Conclusion and Future Directions
Side-effects caused by many β-antagonists are owing to their promiscuous binding to
closely related subtypes of the adrenoceptors (β1AR and β2AR). Therefore, understanding
the molecular basis of β-antagonist selectivity is likely to provide a novel rationale for the
discovery of selective ligands. In this work, we have compared the unbinding process of β1-
and β2-selective antagonists from β1AR and β2AR by applying steered MD simulations and
have shown the potential for a kinetic basis of antagonist selectivity, in addition to the
dynamic binding site selectivity caused by different geometry of the conserved N3446.55.
Remarkably, the calculated average rupture force and work profiles from multiple unbinding
trajectories suggest that the perpendicular to the membrane direction (path B) is likely the
preferable pathway for both ligands to dissociate from β1AR, whereas the lateral direction,
composing helices 5, 6 and 7 (path C) is always favourable in β2AR. The calculated ΔPMF
of the antagonists for these pathways correlates with the observed ligand selectivity between
the receptors. We expect that accuracy of ΔPMF calculations involving hundreds replicates
will increase and provide more precise estimation of the ligand binding affinities. However,
this approach could be challenging for examining binding activities in the high-throughput
scale for many potential ligands.
When pulled in each of the three directions to the extracellular surface, the non-conserved
K3476.58, the E205EL2 -R351EL3 salt bridge, which is localized in the lateral side in β1AR,
and the D193 EL2-K305 EL3 salt bridge, which faces the binding cavity in β2AR, hinder the
antagonists from unbinding in the other directions. The relatively equal force profile of path
A and B are similar to two favourable unbinding channels in β1AR identified recently by
Gonzalez and co-workers (10), while the preference of path C in our short simulations of
unbinding from β2AR is in agreement with the recently published 1–19 μseconds
conventional MD simulations of ligand binding to β2AR (9).
Within the preferable pathways for ligand unbinding from β1AR and β2AR, we found that
the distinct moieties of antagonists have a different pattern of interactions in the receptors.
The unbinding of Esmolol is governed through the interchange of hydrogen bonds of the
ester group, involving K3476.58 in β1AR, whereas ICI-118551 does not form interactions
with this residue. In contrast, the unbinding from β2AR is likely driven by hydrophobic and
aromatic interactions with Y3087.35, H2966.58, F193EL2 and F194EL2 and, thus, the
hydrophobic moiety of ICI-118551 spends more time interacting with these residues than
Esmolol. The ester group of Esmolol forms few hydrogen bonds in β2AR during unbinding.
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By simulating unbinding from the adrenoceptors, we assume that the binding process takes
place in an opposite but a similar fashion; thus, the proposed residues underling the
unbinding likely play important roles during binding as well. The hydrophobic surfaces
between alprenolol and Y3087.35, H2966.58, F193EL2 have been recently observed by Dror
and co-workers in long simulations of alprenolol binding (9).
In our simulations, K3476.58 coordinates the antagonist unbinding by restricting the escape
from one side of the extracellular surface and utilizing a hydrogen bond to translate the
antagonist to the extracellular surface through another route, providing selective features of
antagonist unbinding in β1AR. Interestingly, K3476.58 in human β1AR is replaced by
asparagine in turkey β1AR, which can play a different role in ligand binding and unbinding,
which explains recent simulations of dihydroalprenolol binding that showed the binding
pathway was similar to β2AR (9). In addition, in a recent pharmacological study, it was
observed that the β1AR-selective antagonist, CGP20712A, in human is not selective in
turkey (34). With both species β1AR receptors having identical binding sites, we
hypothesize that the residue difference at the extracellular surface is responsible for the
different binding profiles of antagonists between these two proteins.
Our study suggests a kinetics basis of antagonist selectivity in the adrenoceptors in which
the non-conserved residues at the extracellular surface form selectivity filters that recognize
the molecule from the soluble environment by its shape and physicochemical properties, and
bring it into the binding site through a cascade of specific intermediate interactions. The
mapping of structures taken from the unbinding trajectories by hydrophobic and electrostatic
probes highlights differences in the physicochemical properties of the extracellular surface
(Figure 9). For example, there is preference for a hydrogen bond acceptor region in β1AR
and a hydrophobic region in β2AR, especially in the snapshots where the selective
antagonist forms specific interactions during unbinding (Figure 9B–C, E–D). The kinetics-
based preferable regions are poorly seen in the ligand-receptor complexes, as shown by the
initial structures in Figure 9A,D. Receptor conformations from these unbinding studies can
play an important role within a drug design application, for example by designing a ligand
with unique binding kinetics by docking molecules or fragments within the binding and
unbinding channel, in addition to classical docking to the binding site, or by growing a
ligand in such way that it can interact with the extracellular residues forming the preferable
maps. Although, there is no experimental proof of kinetic basis of antagonist selectivity in
the adrenergic receptors at this moment, our computational study suggests amino acid
residues of the receptor extracellular surface for site-directed mutagenesis studies or
medicinal chemistry optimization to explore this hypothesis experimentally.
In this work, we have simulated the unbinding event of two antagonists that do not cause
conformational changes leading to activation and signalling. The process of agonist binding
and unbinding is thought to be more complicated as it involves a series of conformational
changes in the receptor structure, resulting in formation of the active state. Fluorescence
spectroscopy studies have shown a sequential binding model of agonists in which the partial
agonist, dopamine, has rapid binding, whereas a full agonist, noradrenaline, preserves the
biphasic binding kinetics in β2-AR (35). We anticipate that there are different interactions in
the binding and unbinding pathways of agonists and antagonists. Simulations of the agonist
binding process, in which step-by-step conformational changes of the receptor undergoing a
transition from the inactive conformation towards the active one, may provide novel
molecular features in ligand kinetics, which in turn, could help to interpret ligand efficacy
and facilitate design of selective ligands with desired efficacy. The recently published
crystal structure of β2AR in complex with the Gs protein, representing the active state,
provides the opportunity for a such study (27). Thus, transition from inactive to active states
of β2AR in the presence of ligands with different efficacy using adaptive biasing simulations
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recently performed by Provasi and co-workers revealed energetics of the receptor
conformational space during activation (36). Transition from active to inactive states in the
presence of agonists and atomic details of activation have been recently suggested by Dror
and co-workers (37).
Our simulations in a hydrated lipid bilayer at physiological pH were aimed to approximate
the realistic in vivo environment. However, GPCRs are often subjected to N- or O-
glycosylation within their extracellular regions, which the current computational works on
GPCR simulations and our study have neglected. Pharmacological studies have identified
that the asparagine residues at positions 6N(N - the N-terminus of the receptor), 15N and
187EL2 in β2AR and at position 15N in β1AR are N-glycosylated (38,39). The non-
conserved N187EL2 is located in the second extracellular loop faces the extracellular cavity;
thus, it may be directly involved in ligand binding through paths C and B in β2AR. N187EL2
is replaced by D212EL2 in β1AR, without the capability to be glycosylated. It has been
shown for several GPCRs that the blockage of glycosylation results in non-functional
receptors that are often incapable of ligand binding (40–42). Glycosylation regulates surface
expression and dimerization of β1AR (43). It is not clear how many oligosaccharide chains
are present for each glycosylation site in GPCRs; however, it is expected that it could vary
from a minimum pentasaccharide structure to a complex oligosaccharide structure
containing several oligosaccharide chains (44). Such a 'sweet cloud' confronts the
extracellular cavity and likely influences ligand binding and unbinding, providing further
structural differences between the receptors. The oligosaccharide cloud can form specific
intermediate binding sites, where not only an orthosteric ligand can stick on the way to its
binding site, but also an allosteric ligand could interact with this site to modulate receptor
activation, enlarging the spectrum of the recently proposed putative allosteric binding sites
of β1AR and β2AR (45). Importantly, glycosylation produces a stable hydration shell, which
causes different entropic cost during ligand binding and unbinding compared to a less
ordered hydration shell in the absence of oligosaccharides. Taken together, the next
challenge in understanding the molecular basis of ligand binding and unbinding is
involvement of receptor active states and glycosylation in GPCR simulations.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Structures of β1AR-selective Esmolol and β2AR-selective ICI-118551. Biological activities
are taken from references 5 and 7.
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Figure 2.
The extracellular side of the adrenergic receptors. (A) the β1 adrenergic receptor in the
complex with Esmolol, (B) the β2 adrenergic receptor in the complex with ICI-118551, (C)
the schematic representation of the binding site interactions between Esmolol and the β1
adrenergic receptor, and (D) the schematic representation of the binding site interactions
between ICI-118551 and the β2 adrenergic receptor. The snapshots for the images were
taken from the molecular dynamics trajectories. The binding site residues and residues
involved in ligand unbinding are visualized in the stick-like representation in A and B.
Pulling directions are shown in arrows.
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Figure 3.
The average, rupture force and work profiles of antagonist unbinding from the adrenergic
receptors in three extracellular pathways. The graphs were plotted against ligand separation
from the initial coordinates in the binding site. The unbinding of β1AR-selective Esmolol
and β2AR-selective ICI-118551 are shown in black and red, respectively.
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Figure 4.
Esmolol and ICI-118551 unbinding from the β1 adrenergic receptor on the example of one
representative trajectory shown in the form of the rupture force, work, hydrogen bonds,
hydrophobic and water-mediated contacts projected onto unbinding time and antagonist
separation time from the initial position.
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Figure 5.
The hydrogen bond profile of the ester group during the Esmolol unbinding from the β1 and
β2 adrenergic receptor.
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Figure 6.
Evolution of the distance between the centre of the aromatic ring of F218EL2 and F3597.35
along the unbinding pathway B (A), 30 nseconds of conventional molecular dynamics of the
complexes with Esmolol or ICI-118551 (B) and 30 ns of the unoccupied β1 adrenergic
receptor (C).
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Figure 7.
The lateral channel to the extracellular surface composing helices 5, 6 and 7. The H296-
Y308-N293 hydrogen bond network of interactions in the β2 adrenergic receptor (A, B)
along the ligand unbinding trajectories, radius of gyration of the lateral channel, along
unbinding pathway C (C) and radius of gyration of the lateral channel in 30 nseconds
classical MD of the ligand-receptor complexes (D).
Selvam et al. Page 21
Chem Biol Drug Des. Author manuscript; available in PMC 2012 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 8.
Esmolol and ICI-118551 unbinding from the β2 adrenergic receptor on the example of one
representative trajectory shown in the form of the rupture force, work, hydrogen bonds,
hydrophobic and water-mediated contacts projected onto unbinding time and antagonist
separation time from the initial position.
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Figure 9.
Hydrophobic and hydrogen bond acceptor grids in the structural snapshots of the β1 and β2
adrenergic receptors taken from the antagonist unbinding trajectories.
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Table 1
The atoms of the receptors and ligands to which an external force has been applied to pull Esmolol and
ICI-118551 in three extracellular directions from the β1 and β2 adrenergic receptors
Path Cα atom of a residue in β1/β2 adrenoceptors Ligand atom (Esmolol/ICI-118551)
Path A (TM7, TM1 & TM2) F5.47(233/208) C10/C9
F6.52 (341/290)
S5.46 (232/207)
T3.36 (143/118)
Path B (Straight) F5.47 (233/208) C10/C9
M2.53 (107/82)
T3.36 (143/118)
W6.48 (337/286)
Path C (TM5, TM6 & TM7) I3.40 (146/121) C10/C9
M2.53 (107/82)
T3.36 (143/118)
Y7.43 (367/316)
Chem Biol Drug Des. Author manuscript; available in PMC 2012 August 01.
